This study is an open label study of autologous bone-marrow-derived mesenchymal stem cells (STR04) in participants with ALS. Participants will undergo a screening visit, followed by collection of peripheral blood and bone marrow for the manufacture of STR04. Participants will then receive 4 intravenous doses of STR04, one dose every 12 weeks. The study will be conducted at 3-5 clinical sites in the US.
Autologous stem cell therapy is being studied as an investigational treatment. NECTx is committed to patients and their families as we aim to develop transformational treatments through scientific innovation for life-threatening diseases such ALS.
Check back for further information on NECTx’s clinical trials.